Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Times Interest Earned: 2016-2025

Historic Times Interest Earned for Theravance Biopharma (TBPH) over the last 9 years, with Sep 2025 value amounting to -$11.27.

  • Theravance Biopharma's Times Interest Earned rose 34.51% to -$11.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.01, marking a year-over-year increase of 25.29%. This contributed to the annual value of -$18.44 for FY2024, which is 22.66% up from last year.
  • Theravance Biopharma's Times Interest Earned amounted to -$11.27 in Q3 2025, which was down 174.09% from -$4.11 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Times Interest Earned peaked at -$4.11 during Q2 2025, and registered a low of -$45.29 during Q1 2023.
  • Over the past 3 years, Theravance Biopharma's median Times Interest Earned value was -$17.20 (recorded in 2024), while the average stood at -$19.06.
  • Its Times Interest Earned has fluctuated over the past 5 years, first crashed by 936.98% in 2021, then surged by 83.15% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Times Interest Earned stood at -$26.28 in 2021, then declined by 20.59% to -$31.69 in 2022, then soared by 68.40% to -$10.02 in 2023, then tumbled by 42.85% to -$14.31 in 2024, then soared by 34.51% to -$11.27 in 2025.
  • Its Times Interest Earned stands at -$11.27 for Q3 2025, versus -$4.11 for Q2 2025 and -$22.45 for Q1 2025.